CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study Screening for Atrial Fibrillation With ECG: USPSTF Recommendation Robotics in percutaneous cardiovascular interventions Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention SCAI Expert Consensus Statement Update on Best Practices for Transradial Angiography and Intervention Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review
|<< 1 2 3 4 5 6 7 ...>>|

Review Article2003 Oct;60(2):194-201.

JOURNAL：Catheter Cardiovasc Interv. Article Link

Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory

Klein LW, Kern MJ, Interventional Cardiology Committee of the Society of Cardiac Angiography and Interventions. Keywords: no-reflow phenomenon; CathLab

LINK

Please click on "Article Link" on the right side to get further access.
>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top